| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 3.1 | 3.1 | 4.6 |
| Other income | 0.2 | 0.1 | 0.2 |
| Total income | 3.3 | 3.2 | 4.7 |
| Profit before exceptional items & tax | 0.3 | 0.2 | 0.4 |
| Profit before tax | 0.3 | 0.2 | 0.4 |
| Net profit | 0.2 | 0.2 | 0.3 |
| Operating margin | 9.1% | 6.2% | 8.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -33.30% |
|---|---|
| Net profit, quarter on quarter | +0.00% |
| Revenue, year on year | -32.60% |
BSE results filing, NSE: ISHITADR. Figures extracted from the filing.
Ishita Drugs & Industries Ltd: key numbers
- Share price
- ₹81.99
- Market cap
- ₹24.52 Cr
- Revenue (annual)
- ₹14.66 Cr
- Net profit (annual)
- ₹0.78 Cr
- P/E (TTM)
- 34.7×Sector 47.3×
- Promoter holding
- 50.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ishita Drugs & Industries Ltd
All →Ishita Drugs & Industries Debt & Borrowing: ₹11.75 Cr
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
- Value
- ₹11.75 Cr
Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries Ltd will hold a board meeting on September 22, 2026. The meeting will consider raising funds through working capital and term loans.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd has issued physical letters to shareholders with weblinks for its FY 2025-26 Annual Report. The 33rd AGM is scheduled for September 30, 2026.
Ishita Drugs & Industries Annual General Meeting
Ishita Drugs & Industries Ltd has scheduled its 33rd Annual General Meeting for September 30, 2026. The book closure is set from September 24 to September 30, 2026.
Ishita Drugs & Industries Management Change
Ishita Drugs and Industries Limited has re-appointed Abha Agrawal as a Non-Executive Non-Independent Director, effective October 1, 2026.
Ishita Drugs & Industries Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 33.3% YoY
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3.1 Cr (-42.6% YoY) and net profit of ₹0.2 Cr (-33.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.2 Cr · -33.3% YoY